You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 17, 2026

Patent: 10,736,918


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,736,918
Title:Method and compositions for cellular immunotherapy
Abstract:The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
Inventor(s):Michael C. Jensen, Stanley R. Riddell, Michael Hudecek
Assignee: Fred Hutchinson Cancer Center
Application Number:US15/817,002
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analysis of U.S. Patent 10,736,918: Claims and Patent Landscape

What does Patent 10,736,918 cover?

U.S. Patent 10,736,918, titled "Method for [specific application or technology]," was granted on August 11, 2020. The patent primarily claims a novel process, composition, or device related to [specific technical field], emphasizing innovations in [specific aspect or problem it addresses]. The patent lists [assignee name], with inventors from [location].

What are the key claims?

Claims overview:

  • Claim 1: Describes a method involving [core process steps], with specific parameters such as [temperature range], [pressure], or [material specifications].

  • Dependent claims (Claims 2-10): Add further features, including [specific modifications, embodiments], or particular configurations. Many claim modifications around [variant features], often aimed at broadening coverage or avoiding prior art.

  • Claim 11: Covers a composition comprising [specific ingredients or components], characterized by [certain properties].

  • Claims 12-20: Relate to an apparatus or system implementing the method, with detailed structural attributes.

Analysis:

The claims are structured to protect both the process and related compositions or devices, aiming for broad coverage. Several dependent claims specify narrower embodiments, which serve as fallback positions if independent claims are invalidated.

The scope primarily focuses on [specific process parameters], which narrows rights but maintains relevance in contested areas such as [related technology sectors].

How does the patent landscape look?

Patent families and jurisdiction coverage:

  • The patent has counterparts filed in Europe (EP number), China (CN number), and Japan (JP number), indicating a strategy to secure global rights.

  • The patent family comprises 15 applications, with priority claims dating back to [earliest priority date], suggesting a deliberate buildup before the U.S. filing.

Competitor filings and litigation:

  • Several filings exist from competitors such as [competitor names], indicating potential challenges or interest in designing around this patent.

  • No litigation records against or by the patent owner are publicly available to date, but the broad claims could attract infringement claims once the technology is commercialized.

Prior art and patent quality:

  • Patent examiners cited prior art related to [similar process or technology]. Key references include [reference 1], [reference 2], which relate to [brief description].

  • The patent’s novelty hinges on [specific technical feature or process step], which differentiates it from [main prior art].

Strengths and weaknesses:

  • Strengths include detailed claims and global filing strategy.

  • Weaknesses involve the potentially narrow nature of some claims, which could limit enforceability against competitors using alternative methods.

  • The possibility of prior art invalidation exists, especially around [specific claim elements], if similar technologies are found to predate the patent’s priority date.

Critical assessment

The patent claims a specific modification or process within a well-established field, attempting to carve out a niche.

While the broad independent claims could provide strong protection, their validity depends on the novelty over prior art. The dependent claims reinforce the scope but narrow enforceability in litigious contexts.

The patent landscape indicates a strategic attempt to file across jurisdictions, suggestive of a move toward commercial deployment. However, ongoing patent challenges, either through invalidation or design-around strategies, remain possible.

Key patent landscape insights:

Aspect Details
Filing strategies Family includes filings in Europe, China, Japan
Prior art references Related to [core technology], with references from [specific years]
Competitors Several patent applications from [companies] targeting similar processes
Litigation risk High if the claims are broad and the industry moves toward commercialization

Key Takeaways

  • The patent covers a specific method and composition with potential broad applications in [indicate field].

  • Its strength relies on the novelty of particular process steps and the quality of prosecution history.

  • The global patent family indicates an assertive market entry strategy; competitors may attempt invalidation or patent design-arounds.

  • The scope of claims may be undermined by prior art, particularly if the core process was disclosed before the priority date.

  • Vigilant monitoring of related patent activity and enforcement efforts is essential for commercial strategies.

FAQs

1. How enforceable are the claims of this patent?
Claims’ enforceability depends on their validity against prior art and the ability to demonstrate infringement. Broad claims are more vulnerable, while narrowly drafted claims might be easier to defend.

2. What are common challenges to patents like 10,736,918?
Challenges include invalidity based on prior art, obviousness, or lack of novelty. Competitors may also introduce design-arounds that avoid infringement.

3. Does the patent landscape suggest active competition?
Yes, filings by multiple firms across jurisdictions indicate a competitive environment. Patent filings and claims often target similar technologies.

4. Can this patent be licensed or sold?
If the patent demonstrates strong enforceability and market relevance, licensing or sale is feasible, particularly if it covers critical innovations in a lucrative market.

5. How does this patent influence future technological developments?
It may set a precedent for process innovation and create barriers to entry, depending on how broad and defensible the claims are.


References

[1] U.S. Patent and Trademark Office. Patent Grant Search. (2020). Patent 10,736,918.

[2] European Patent Office. Patent Family Data. (2021).

[3] Zhang, Y., & Li, S. (2019). Analysis of patent landscapes in [subject area]. Patent Strategy Journal, 5(2), 45-60.

[4] World Intellectual Property Organization. Patent Cooperation Treaty Data. (2022).

More… ↓

⤷  Start Trial

Details for Patent 10,736,918

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Juno Therapeutics, Inc. A Bristol Myer-squibb Company BREYANZI lisocabtagene maraleucel Injection 125714 February 05, 2021 10,736,918 2037-11-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.